연구
-
-
연구
-
연구업적
연구업적
최근 5년 연구업적 현황
| 연도 | 2023년 | 2022년 | 2021년 | 2020년 | 2019년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 173편 | 163편 | 184편 | 135편 | 144편 |
| 공동 | 120편 | 115편 | 136편 | 168편 | 167편 | |
| 합계 | 293편 | 278편 | 320편 | 303편 | 311편 | |
1391. Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer.
Lira ME1, Kim TM, Huang D, Deng S, Koh Y, Jang B, Go H, Lee SH, Chung DH, Kim WH, Schoenmakers EF, Choi YL, Park K, Ahn JS, Sun JM, Ahn MJ, Kim DW, Mao M.
J Mol Diagn. 2013 Jan;15(1):51-61. doi: 10.1016/j.jmoldx.2012.08.006. Epub 2012 Dec 12.
Link
1390. Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib.
Park JH1, Kim TM, Keam B, Jeon YK, Lee SH, Kim DW, Chung DH, Kim YT, Kim YW, Heo DS.
Clin Lung Cancer. 2013 Jul;14(4):383-9. doi: 10.1016/j.cllc.2012.10.007. Epub 2013 Jan 10.
Link
1389. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.
Kim S1, Kim TM, Kim DW, Go H, Keam B, Lee SH, Ku JL, Chung DH, Heo DS.
J Thorac Oncol. 2013 Apr;8(4):415-22. doi: 10.1097/JTO.0b013e318283dcc0.
Link
1388. Anti-cancer activity of gemcitabine against natural killer cell leukemia/lymphoma.
Kim TM1, Kim S, Ahn YO, Lee SH, Kim DW, Heo DS.
Leuk Lymphoma. 2013 Jul 29. [Epub ahead of print]
Link
1387. Clinicopathologic implication of A20/TNFAIP3 deletion in diffuse large B-cell lymphoma: an analysis according to immunohistochemical subgroups and rituximab treatment.
Paik JH1, Go H, Nam SJ, Kim TM, Heo DS, Kim CW, Jeon YK.
Leuk Lymphoma. 2013 Sep;54(9):1934-41. doi: 10.3109/10428194.2012.762511. Epub 2013 Feb 16.
Link
1386. Exosome derived from epigallocatechin gallate treated breast cancer cells suppresses tumor growth by inhibiting tumor-associated macrophage infiltration and M2 polarization.
Jang JY1, Lee JK, Jeon YK, Kim CW.
BMC Cancer. 2013 Sep 17;13:421. doi: 10.1186/1471-2407-13-421.
Link
1385. ANT2 suppression by shRNA may be able to exert anticancer effects in HCC further by restoring SOCS1 expression.
Jang JY1, Jeon YK, Lee CE, Kim CW.
Int J Oncol. 2013 Feb;42(2):574-82. doi: 10.3892/ijo.2012.1736. Epub 2012 Dec 13.
Link
1384. ANT2 suppression by shRNA restores miR-636 expression, thereby downregulating Ras and inhibiting tumorigenesis of hepatocellular carcinoma.
Jang JY1, Lee YS, Jeon YK, Lee K, Jang JJ, Kim CW.
Exp Mol Med. 2013 Jan 10;45:e3. doi: 10.1038/emm.2013.1.
Link
1383. Sequence-Dependent Radiosensitization of Histone Deacetylase Inhibitors Trichostatin A and SK-7041.
Kim JH1, Kim IH2, Shin JH1, Kim HJ1, Kim IA3.
Cancer Res Treat. 2013 Dec;45(4):334-42. doi: 10.4143/crt.2013.45.4.334. Epub 2013 Dec 31.
Link
1382. RANTES polymorphisms and the risk of graft-versus-host disease in human leukocyte antigen-matched sibling allogeneic hematopoietic stem cell transplantation.
Shin DY1, Kim I, Kim JH, Lee YG, Kang EJ, Cho HJ, Lee KH, Kim HJ, Park EH, Lee JE, Bae JY, See CJ, Yoon SS, Park SS, Han KS, Park MH, Hong YC, Park S, Kim BK.
Acta Haematol. 2013;129(3):137-45. doi: 10.1159/000343273. Epub 2012 Nov 30.
Link